This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.


Vitamin D Status and Cardiometabolic Risk Factors in Long-Term Psychiatric Inpatients

Vitamin D Status and Cardiometabolic Risk Factors in Long-Term Psychiatric Inpatients

Vertical divider


Objective: Low vitamin D levels are common in psychiatric patients, but a need for vitamin D supplementation in these individuals remains controversial. Low vitamin D levels are reportedly associated with high prevalence of cardiometabolic risk factors, and both are common in psychiatric patients, but the relationship between diagnosis and severity of illness and cardiometabolic risk status and the effect of vitamin D treatment on them is not known. We studied these relationships and effect of vitamin D3 treatment on them in 290 long-term psychiatric inpatients.

Method: All patients admitted to the hospital during April 2009-March 2010 who agreed to 25-hydroxyvitamin-D testing were included. Serum 25-hydroxyvitamin D level, Brief Psychiatric Rating Scale (BPRS) score, body mass index, blood pressure, and fasting levels of blood glucose, triglycerides, high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C) were measured at baseline, and changes after vitamin D3 treatment for up to 12 months were observed. For the purposes of this study, 25-hydroxyvitamin-D levels < 32 ng/mL were considered as “low”; < 20 ng/mL, as “insufficient”; and < 12 ng/mL, as “deficient.”

Results: A serum 25-hydroxyvitamin-D level < 32 ng/mL was found in 90.0% of patients, and a level < 20 ng/mL was found in 48.6% of patients. A BPRS score > 36 was present in 56.0% of patients; obesity, in 75.7%; hypertension, in 44.8%; low HDL-C, in 43.6%; high triglycerides, in 31.2%; high LDL-C, in 17.8%; and increased glucose, in 14.6%. Serum 25-hydroxyvitamin-D levels correlated poorly with BPRS score and the other variables listed above (R, −0.02 to −0.22). After vitamin D3 treatment, 25-hydroxyvitamin-D level increased to ≥ 20 ng/mL in all patients and ≥ 32 ng/mL in 85% of patients, but despite > 124% increase in mean 25-hydroxyvitamin-D level, mean improvement in other variables was < 12%.

Conclusions: Nearly half of our patients had vitamin D levels < 20 ng/mL, putting them at risk for poor bone health and requiring vitamin D supplementation. Cardiometabolic risk factors were also highly prevalent, but correlated poorly with vitamin D levels in their severity. Increasing vitamin D levels to ≥ 32 ng/mL was not associated with improvement in BPRS score or any cardiometabolic risk factor, emphasizing that intensification of therapeutic measures other than vitamin D supplementation is required.

Prim Care Companion CNS Disord 2012;14(1):doi:10.4088/PCC.11m01221

Submitted: May 24, 2011; accepted August 10, 2011.

Published online: February 9, 2012.

Corresponding author: Anwar K. Abdullah, MD, 12909 Scrimshaw Cir, Chester, VA 23836 (

Psychiatric patients have been reported to have lower vitamin D levels than the general population.1-5 Cardiovascular risk factors including hypertension, diabetes, obesity, and metabolic syndrome have been reported to be associated with vitamin D levels below 32 ng/mL.6-9 As cardiometabolic risk factors are more common in psychiatric patients than in the general population and are also aggravated by antipsychotic drugs,10,11 low vitamin D levels may be of added significance in psychiatric patients. The relationship of vitamin D status of psychiatric patients with their diagnosis and severity of psychiatric illness and cardiometabolic risk status has never been reported. This study reports serum 25-hydroxyvitamin-D (25D) levels in long-term patients at a state psychiatric hospital, the relationship of 25D levels with diagnosis and severity of psychiatric illness and demographic and cardiometabolic variables, and the effects on these variables of increasing the levels to ≥ 32 ng/mL.


All patients admitted to our hospital during April 2009-March 2010 who agreed to 25D testing were included. All patients treated with vitamin D were followed up approximately every 4 months for up to 1 year. The study was approved by the hospital’s institutional review board.

Age, gender, race, blood collection date, and duration of hospital stay on that date were recorded. Patients were grouped as follows according to their primary Axis I diagnosis: (1) schizophrenic disorders (ICD-9 codes 295), (2) affective disorders (ICD-9 codes 296), and (3) other psychiatric disorders. Brief Psychiatric Rating Scale (BPRS)12 scores were used as approximate measures of severity of psychiatric illness. A score of > 36, which would include individuals with at least 3 residual psychiatric symptoms scoring a 5 (moderately severe) or 4 symptoms scoring a 4 (moderate), was considered high. Blood pressure was measured, and body mass index (BMI) was calculated as weight (kg)/height (m)2. Fasting blood samples were tested for glucose, triglycerides, high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C) at the hospital’s clinical laboratories. Measurement of 25D was done by LabCorp, Burlington, North Carolina, using an immunochemiluminometric assay measuring D2 and D3 together and reporting total 25-hydroxyvitamin-D.13

For purposes of this study, 25D levels < 32 ng/mL were considered as “low”; < 20 ng/mL, as “insufficient”; and < 12 ng/mL, as “deficient.” All patients with 25D < 32 ng/mL who agreed to vitamin D treatment were given 4,000 international units (IU) of vitamin D3 (cholecalciferol) orally once daily. Other treatments were continued as prescribed by the patients’ physicians. At the first follow-up, if 25D level was > 40 ng/mL, vitamin D3 dose was reduced to 2,000 IU/d. At subsequent follow-ups, the dose was further reduced to 1,000 IU if 25D level was > 40 ng/mL, increased to 4,000 IU if 25D level was < 32 ng/mL, and continued at 2,000 IU/d if 25D level was 32-40 ng/mL.

Statistical analyses were done and graphs were generated using Microsoft Excel 2007. The Student t test was used to compare means, and percentages were compared by 2-tailed 2-proportion z test. Significance level was set at < .05. Pearson correlation was performed to explore associations between 25D and other variables.


Prevalence of Vitamin D Deficiency and Other Variables

In the 290 patients tested at baseline (Table 1), a 25D level of < 32 ng/mL was found in 261 (90.0%), < 20 ng/mL in 141 (48.6%), and < 12 ng/mL in 45 (15.5%). Of the cardiometabolic risk factors, obesity (BMI > 25 kg/m2) was most frequent (75.7%), followed by elevated systolic and/or diastolic blood pressure (44.8%), low HDL-C (43.6%), elevated fasting triglycerides (31.2%), elevated LDL-C (17.8%), and elevated fasting blood glucose (14.6%).

Table 1

Click figure to enlarge

clinical points
  • Low vitamin D levels are reportedly associated with cardiometabolic risk factors such as obesity, hypertension, diabetes, and dyslipidemia, which are known to be common in psychiatric patients.
  • Nearly half of long-term hospitalized psychiatric patients had vitamin D levels < 20 ng/mL, putting them at risk for poor bone health, indicating the need for vitamin D screening and supplementation in such populations.
  • Cardiometabolic risk factors were also common, but correlated poorly with vitamin D levels. Increasing vitamin D levels to ≥ 32 ng/mL did not improve BPRS score or any cardiometabolic risk factor, suggesting that intensification of therapeutic measures other than vitamin D supplementation is required.

Vitamin D Levels and Other Variables at Baseline

There were 185 patients with schizophrenic disorders, 49 with affective disorders, and 56 with all other psychiatric diagnoses. The mean 25D level (21.2 ng/mL) and prevalence of low 25D (88.6%) in the schizophrenic group were not significantly different from those in the other 2 groups (20.7 and 19.7 ng/mL, and 89.8% and 92.9%, respectively, in the affective disorders and all other psychiatric diagnoses groups).

The sample comprised 102 whites and 188 nonwhites including 177 African-Americans and 11 Hispanics and Asians. The mean ± SD 25D level of the sample was 20.9 ± 9.4 ng/mL, with a range of 4.0-71.6 ng/mL. Baseline 25D values of each patient by age, race, and gender are displayed in Figure 1, and other details are presented in Table 2.

Mean 25D level at baseline was significantly lower (P < .05) and prevalence of low 25D (< 32 ng/mL) was significantly higher (P < .05) in nonwhites and in patients with a shorter hospital stay (< 12 months) and increased LDL-C (≥ 130 mg/dL). In the group aged < 25 years and in the group with higher BMI (≥ 30 kg/m2), mean 25D level was significantly lower (P < .05), but prevalence of low 25D was not significantly different from those in the 2 older age groups. Mean 25D level was low (< 21.8 ng/mL) and prevalence of low 25D was high (> 85.7%) in all patient groups, but the results were not significantly different in men and women or during summer and winter, or in patients with low and high BPRS scores; normal and increased blood pressure, fasting blood glucose, and fasting triglycerides; or normal and decreased HDL-C levels. There was a weak significant negative correlation of 25D with LDL-C levels (R = −0.22, P < .001) and a weak significant positive correlation with age (R = −0.13, P = .003), but no significant correlation with duration of hospital stay, BPRS score, BMI, blood pressure, fasting blood glucose, fasting triglycerides, or HDL-C (Table 2). In summary, patients with low 25D were more often nonwhite and younger, had higher BMI, had higher LDL-C, and had been in the hospital for a shorter period.

Figure 1

Click figure to enlarge

Table 2

Click figure to enlarge

Changes in Vitamin D Levels and Other Variables After Vitamin D3 Treatment

Of the 261 patients with 25D level < 32 ng/mL at baseline, 235 agreed to take vitamin D treatment. Since many patients were discharged from the hospital before their next follow-up and some refused to continue vitamin D treatment or allow follow-up testing, only 145, 90, and 67 patients were available for follow-up at ~ 4, 8, and 12 months after treatment, respectively (Table 3).

Table 3

Click figure to enlarge

Mean baseline 25D level for all 290 patients was 20.9 ng/mL (range, 4.0-71.6 ng/mL). It was < 32 ng/mL in 261, < 20 ng/mL in 141, < 12 ng/mL in 45, and ≥ 32 ng/mL in 29 patients, including 2 patients with > 50 ng/mL (1 patient with 71.6 ng/mL and 1 with 56.1 ng/mL) (Table 4).

Table 4

Click figure to enlarge

Mean 25D level for 261 patients with 25D levels < 32 was 18.8 ng/mL at baseline. Twenty-six of the patients refused vitamin D treatment. Mean baseline 25D level for 235 patients starting treatment was 18.9 ng/mL. In 145 patients completing treatment with vitamin D3 4,000 IU/d for ~ 4 months, 25D increased to 45.2 ng/mL, an increase of 139% from baseline (Table 4). Of those patients, 119 achieved 25D levels ≥ 32 ng/mL, including 50 equal to or exceeding 50 ng/mL, and the highest level attained was 87.9 ng/mL. But 3 patients remained < 20 ng/mL, and 1 remained < 12 ng/mL (Table 4).

Of the 90 patients completing treatment for ~ 8 months, 55 who had attained 25D > 40 ng/mL at 4-month follow-up maintained their 25D level at ≥ 32 ng/mL even after reducing their vitamin D doses to 2,000 IU/d. However, of the 35 patients whose levels were < 40 ng/mL and who continued on 4,000 IU/d, 9 remained at a 25D level of < 32 ng/mL, and 1 had a level of < 20 ng/mL, but none had a level < 12 ng/mL (Table 4).

Of the 67 patients completing ~ 12 months’ treatment, 35 maintained their 25D level ≥ 32 ng/mL at a dose of 1,000 IU/d of vitamin D3, and 22 required 2,000 IU/d to maintain this level. Ten patients did not achieve 32 ng/mL even with 4,000 IU/d, but all of them did attain > 20 ng/mL (Table 4).

The mean BPRS score at baseline was 38.7, which did not change significantly after vitamin D treatment. Mean BPRS change from baseline was less than 5%, although in 16.1% of treated patients, BPRS score improved to < 36 at 12-month follow-up (Table 3).

The mean BMI was 30.0 kg/m2 at baseline, which increased to 31.6, 32.1, and 31.3 kg/m2, respectively, at ~ 4-, 8-, and 12-month follow-ups. Very few patients (1.6%) were able to reduce their BMI to normal even after 12 months of vitamin D3 treatment (Table 3).

Mean systolic and diastolic blood pressure were not significantly different from baseline, and mean change from baseline was < 5% at follow-up points up to 12 months, although 19.1%-24.6% of patients improved their systolic and/or diastolic blood pressure to normal (Table 3).

Mean fasting blood glucose increased significantly from 90.2 mg/dL at baseline to 96.4 mg/dL, 97.4 mg/dL, and 96.6 mg/dL at ~ 4, 8, and 12 months, respectively (P < .04). Mean increase was 6.8%, 8.0%, and 7.1%, and 5.2%, 6.8%, and 10.6% of patients had normalized levels at ~ 4-, 8-, and 12-month follow-up, respectively (Table 3).

Fasting triglycerides, HDL-C, and LDL-C showed no significant improvement from baseline except that mean HDL-C increased significantly from 47.8 mg/dL at baseline to 50.8 mg/dL at 8 months (P < .03), but at 12-month follow-up it was 45.9 mg/dL, which was not significantly different from baseline (Table 3).


Prevalence and Severity of Vitamin D Deficiency

To our knowledge, this is the first report of vitamin D status of long-term hospitalized psychiatric patients in the United States. The 2010 report of the Food and Nutrition Board of the Institute of Medicine (IOM)14 concluded that persons are “at risk of deficiency of vitamin D at serum 25D of < 12 ng/mL, and that ≥ 20 ng/mL is sufficient for > 97.5% of the American population for skeletal health.” As shown in Table 1, nearly half of our patients had 25D levels < 20 ng/mL, which may not be sufficient in vitamin D for skeletal health. Some authorities have suggested that a minimum 25D level of 32 ng/mL may be required to meet nonskeletal needs for vitamin D,15,16 but according to IOM,14 evidence for this is inconclusive. Therefore, the significance of a 25D level of ≥ 20 but < 32 ng/mL in 120 (or 41.4%) of our patients at baseline (Table 1) is uncertain.

The mean baseline 25D level in this study was 20.9 ± 9.4 ng/mL (Table 2), which was lower than the levels found in other studies: 24 ng/mL, found in a nationally representative sample of American adults (National Health and Nutrition Examination Survey [NHANES]-2004)17; 26.1 ng/mL, found in residents of southern Arizona18; and 67.7 nmol/L (27.1 ng/mL), found in a survey of the Canadian population.19 The level was higher in our psychiatric patients than in general medical inpatients of an acute care hospital in Boston, Massachusetts20 (15.9 ng/mL), a general medical hospital in Italy21 (13.1 ng/mL), and in psychiatric inpatients and outpatients in Norway8 (43.1 nmol/L, or 17.2 ng/mL) and Australia7 (46.4 nmol/L, or 18.5 ng/mL). All 17 psychiatric inpatients in one London hospital22 (< 25 nmol/L, or < 10 ng/mL) and 11 of 12 psychiatric inpatients in another London hospital9 (< 20 ng/mL) were found deficient in vitamin D. In our patients, the prevalence of low 25D was not as high, since only 48.6% of them had 25D levels < 20 ng/mL (Table 1). Some of these differences may be due to differences in methods for 25D assay used at different laboratories.23

Vitamin D Deficiency and Demographic Characteristics

Our findings of lower mean 25D and higher prevalence of low 25D in nonwhites compared to whites were similar to those reported in 2 US national surveys (NHANES 1988-2001 and NHANES 2001-2004),17 but, unlike these surveys, our study found no significant difference between males and females and lower mean 25D level in younger (< 25 years) than in older age groups (Tables 2 and 3). The latter finding may be due to the small number of patients younger than 25 years at our hospital or related to their shorter length of hospital stay. We found that patients who had been in the hospital for > 12 months had a significantly higher mean 25D level and lower prevalence of low 25D than those who were in the hospital for < 3 months (Table 2). This may be due to their healthier lifestyle with regard to diet and physical activity in the controlled environment of the long-term psychiatric hospital compared to the lifestyle of those outside, but it was not enough to increase their mean 25D level to ≥ 32 ng/mL. In the NHANES surveys, mean 25D concentrations were significantly higher in summer than in winter,24 but we found no significant difference in mean 25D level or prevalence of low 25D between the 2 seasons (Tables 2 and 3). This may be due to the small number (25 of 290) of patients who had their baseline 25D level tested in the winter in this study, and perhaps also because their levels of physical activity and exposure to sun were not very different in the 2 seasons in the moderate climate of the area.

Vitamin D Deficiency and Cardiometabolic Risk Factors

As shown in Table 2, prevalence of cardiometabolic risk factors was high among our patients, especially obesity, hypertension, low HDL-C, and high fasting triglycerides. Elevated LDL-C and fasting blood glucose were also common but relatively less frequent. Several investigators have reported association of low vitamin D levels with obesity,4 hypertension,25 diabetes,26 and dyslipidemias.27 We also found decreased mean 25D levels in cases with obesity, diabetes, and increased LDL-C, but not hypertension, and there was no significant correlation between the severity of the associated risk factors and degree of 25D deficiency. This makes it unlikely that low vitamin D levels played a significant role in the causation of these risk factors.

Vitamin D3 Doses and Correction of Vitamin D Deficiency

Optimal vitamin D3 doses needed to correct low 25D are not established. Doses reported in the literature vary from 600,000 IU intramuscular once per year28 to 1,000 IU orally once daily.17 The tolerable upper limit for safe vitamin D3 administration proposed by the IOM Food and Nutrition Board in 1997 is 2,000 IU/d, but a review29 based on data published later, in 2007, concluded that doses up to 10,000 IU/d cause no toxic effect. We chose to start at a dose of 4,000 IU/d and decrease it to 2,000 and then 1,000 IU/d depending on response. We found that patients with lower 25D levels at baseline generally required higher doses of vitamin D3 for longer periods to normalize their 25D level, but the dose response was quite variable and unpredictable in many cases.

All of our patients attained 25D levels of ≥ 20 ng/mL, and 57 of the 67 patients who completed treatment for ~ 12 months achieved ≥ 32 ng/mL, but 10 patients remained at levels < 32 ng/mL (Table 4). The reasons for poor response may be insufficient vitamin D doses or noncompliance with medication, increased catabolism of vitamin D in liver by drugs (eg, barbiturates, phenytoin, glucocorticoids), decreased hepatic synthesis of 25D in advanced liver disease, intestinal malabsorption of vitamin D by disease or drugs such as orlistat or cholestyramine, or excessive loss of 25D in urine in nephrotic syndrome.6 Of the 10 patients who showed poor response, 1 had nephrotic syndrome, 2 were taking orlistat, and 5 had their vitamin D3 dose reduced at the previous follow-up (from 2,000 IU to 1,000 IU/d in 2 patients and from 4,000 IU to 2,000 IU/d in 2 patients), and in 2 patients the reason could not be determined.

No patient developed hypercalcemia, and the maximum 25D level attained by any patient at any time during treatment was 87.9 ng/mL, well below the level of 150 ng/mL that is generally considered safe.30 However, there are reports of 25D > 89 ng/mL in 59.4% of cases of ischemic heart disease versus 22.1% of controls31 and a 2-fold increased risk of pancreatic cancer associated with 25D > 100 nmol/L (or > 40 ng/mL),32 and, because of such reports, IOM14 has expressed concern about undesirable long-term effects at serum 25D levels above 50 ng/mL. Nearly half of our prompt responders to vitamin D3 at every follow-up had 25D ≥ 50 (Table 4), requiring reduction of their vitamin D3 doses. Among the 29 patients with 25D ≥ 32 at baseline who were not treated with vitamin D, 2 had 25D > 50 ng/mL. Whether any intervention to reduce 25D to < 50 ng/mL is required in such patients is not known.

Correction of Vitamin D Deficiency and Improvement in Cardiometabolic Risk Factors

One systematic review concluded that vitamin D supplementation may reduce cardiovascular disease mortality,33 another found no significant effect on cardiometabolic outcomes,34 and a third review was inconclusive.35 We found that although low vitamin D levels occurred frequently together with many cardiometabolic risk factors and 25D increased by > 124% by vitamin D3 supplementation, there was no significant improvement in any of the cardiometabolic risk factors studied, and some (eg, BMI and fasting blood glucose) worsened even as 25D improved (Table 3). Jorde et al36 also found no improvement in cardiovascular risk factors after correction of low 25D by vitamin D3 for 1 year. It is noteworthy that Tzotzas et al37 found that lipid levels and insulin resistance improved significantly after 10% reduction in BMI due to a 20-week low-calorie diet, and mean 25D level also improved from 15.4 ng/mL at baseline to 18.3 ng/mL at the end of study even without vitamin D supplementation. Prospective cohort studies from the United States38 and Europe39 have found independent associations of low 25D with cardiovascular mortality. Our findings and those of other studies cited above34,36,37 suggest that if vitamin D deficiency affects cardiovascular disease and mortality, it is probably by mechanisms other than by improving these risk factors. Large randomized controlled trials such as those currently underway40 may resolve these issues.

This study documents for the first time the lack of correlation between degree of decrease in 25D and diagnosis or severity of psychiatric illness or cardiometabolic risk factors. The long-term hospital setting provided us the opportunity to treat patients with vitamin D and follow them for up to 12 months. However, the number of patients completing treatment for 12 months was small, and this study was not a randomized controlled trial planned primarily to study treatment effect. Most of the patients achieved 25D levels > 20 ng/mL after ~ 4 months of receiving vitamin D3 4,000 IU/d, and it is possible that for many of them doses of 600-800 IU/d, as recommended by IOM,14 may have been sufficient. However, many patients needed doses of 2,000 or 4,000 IU/d for longer periods, and a few did not reach 32 ng/mL even at a dose of 4,000 IU/d, while others reached > 50 ng/mL on smaller doses, indicating that response to oral vitamin D3 is not uniform (Table 4). Additional research is needed to determine any benefit of increasing 25D levels to ≥ 32 ng/mL and the optimum dose and duration of vitamin D treatment to achieve and maintain a 25D level appropriate for both skeletal and extraskeletal health without causing long-term untoward effects.

In conclusion, in this study of vitamin D status of long-term psychiatric inpatients, low 25D was common, and the patients’ mean 25D level was lower than those reported in the general population in the United States, Canada, and Europe, but higher than in acute general medical patients in the United States and in psychiatric patients in Norway, Australia, and the United Kingdom. There was no correlation between 25D levels and either diagnosis or severity of psychiatric illness. Cardiometabolic risk factors including obesity, hypertension, diabetes, and dyslipidemias were also highly prevalent, but their severity did not correlate with severity of low 25D. Correction of low 25D was easy, inexpensive, and without side effects over the course of 1 year of follow-up, but the doses of vitamin D3 required were variable, and correction of low 25D was not associated with significant improvement in BPRS score or any cardiometabolic risk factor. These findings suggest that while vitamin D supplementation may be of questionable value in improving patients’ psychiatric illness or cardiometabolic risk factors, nearly half of these patients had 25D levels < 20 ng/mL, putting them at risk of vitamin D insufficiency for bone health and requiring vitamin D supplementation.

Drug names: cholestyramine (Locholest and others), orlistat (Xenical), phenytoin (Dilantin, Phenytek, and others).

Author affiliations: Central State Hospital, Petersburg (Drs Abdullah, Khan, Mustafa, and Davis); and Department of Physical Medicine and Rehabilitation, Medical College of Virginia, Richmond (Dr Qutubuddin), Virginia.

Potential conflict of interest: None reported.

Funding support: None reported.

Acknowledgments: The authors acknowledge the contribution of Scott Turpin, MD, in planning and design of this work; the help of Gladys Blowe, NP, and Mohan Vaidy, MD, in data collection; and Donna Moore, PsyD, for reviewing the manuscript. All of the acknowledged individuals are affiliated with Central State Hospital, Petersburg, Virginia, and none report a potential conflict of interest.


1. Schneider B, Weber B, Frensch A, et al. Vitamin D in schizophrenia, major depression and alcoholism. J Neural Transm. 2000;107(7):839-842. PubMed doi:10.1007/s007020070063

2. Berk M, Jacka FN, Williams LJ, et al. Is this D vitamin to worry about? vitamin D insufficiency in an inpatient sample. Aust N Z J Psychiatry. 2008;42(10):874-878. PubMed doi:10.1080/00048670802345516

3. Cardinal RN, Gregory CA. Osteomalacia and vitamin D deficiency in a psychiatric rehabilitation unit: case report and survey. BMC Research Notes 2009;2:82. Accessed December 10, 2010.

4. Berg AO, Melle I, Torjesen PA, et al. A cross-sectional study of vitamin D deficiency among immigrants and Norwegians with psychosis compared to the general population. J Clin Psychiatry. 2010;71(12):1598-1604. PubMed doi:10.4088/JCP.09m05299yel

5. Ganji V, Milone C, Cody MM, et al. Serum vitamin D concentrations are related to depression in young adult US population: the Third National Health and Nutrition Examination Survey. Int Arch Med. 2010;3(29):1-8. PubMed

6. Holick MF. Vitamin D deficiency. N Engl J Med. 2007;357(3):266-281. PubMed doi:10.1056/NEJMra070553

7. Reddy Vanga S, Good M, Howard PA, et al. Role of vitamin D in cardiovascular health. Am J Cardiol. 2010;106(6):798-805. PubMed doi:10.1016/j.amjcard.2010.04.042

8. Martins D, Wolf M, Pan D, et al. Prevalence of cardiovascular risk factors and the serum levels of 25-hydroxyvitamin D in the United States: data from the Third National Health and Nutrition Examination Survey. Arch Intern Med. 2007;167(11):1159-1165. PubMed doi:10.1001/archinte.167.11.1159

9. Cheng S, Massaro JM, Fox CS, et al. Adiposity, cardiometabolic risk, and vitamin D status: the Framingham Heart Study. Diabetes. 2010;59(1):242-248. PubMed doi:10.2337/db09-1011

10. McEvoy JP, Meyer JM, Goff DC, et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res. 2005;80(1):19-32. PubMed doi:10.1016/j.schres.2005.07.014

11. Amiel JM, Mangurian CV, Ganguli R, et al. Addressing cardiometabolic risk during treatment with antipsychotic medications. Curr Opin Psychiatry. 2008;21(6):613-618. PubMed doi:10.1097/YCO.0b013e328314b74b

12. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale (BPRS): recent developments in ascertainment and scaling. Psychopharmacol Bull. 1988;24(1):97-99.

13. LabCorp. Vitamin D, 25-Hydroxy, Test Number 081950, CPT Code 82306. Accessed December 27, 2010.

14. Institute of Medicine. Reference Intakes for Calcium and Vitamin D: Report Brief. November 2010. Accessed December 19, 2010.

15. Hollis BW. Circulating 25-hydroxyvitamin D levels indicative of vitamin D sufficiency: implications for establishing a new effective dietary intake recommendation for vitamin D. J Nutr. 2005;135(2):317-322. PubMed

16. Bischoff-Ferrari HA, Giovannucci E, Willett WC, et al. Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomes. Am J Clin Nutr. 2006;84(1):18-28. PubMed

17. Ginde AA, Liu MC, Camargo CA Jr. Demographic differences and trends of vitamin D insufficiency in the US population, 1988-2004. Arch Intern Med. 2009;169(6):626-632. PubMed doi:10.1001/archinternmed.2008.604

18. Jacobs ET, Alberts DS, Foote JA, et al. Vitamin D insufficiency in southern Arizona. Am J Clin Nutr. 2008;87(3):608-613. PubMed

19. Langlois K, Greene-Finestone L, Little J, et al. Vitamin D status of Canadians as measured in the 2007 to 2009 Canadian Health Measures Survey. Health Rep. 2010;21(1):47-55. PubMed

20. Thomas MK, Lloyd-Jones DM, Thadhani RI, et al. Hypovitaminosis D in medical inpatients. N Engl J Med. 1998;338(12):777-783. PubMed doi:10.1056/NEJM199803193381201

21. Muscarella S, Filabozzi P, D’ Amico G, et al. Vitamin D status in inpatients admitted to an internal medicine department. Horm Res. 2006;66(5):216-220. PubMed doi:10.1159/000094989

22. Tiangga E, Gowda A, Dent JA. Vitamin D deficiency in psychiatric in-patients and treatment with daily supplements of calcium and ergocalciferol. The Psychiatrist. 2008;32(10):390-393. doi:10.1192/pb.bp.107.019109

23. Binkley N, Krueger D, Lensmeyer G. 25-hydroxyvitamin D measurement, 2009: a review for clinicians. J Clin Densitom. 2009;12(4):417-427. PubMed doi:10.1016/j.jocd.2009.06.001

24. Looker AC, Pfeiffer CM, Lacher DA, et al. Serum 25-hydroxyvitamin D status of the US population: 1988-1994 compared with 2000-2004. Am J Clin Nutr. 2008;88(6):1519-1527. PubMed doi:10.3945/ajcn.2008.26182

25. Feneis JF, Arora RR. Role of vitamin D in blood pressure homeostasis. Am J Ther. 2010;17(6):e221-e229. PubMed doi:10.1097/MJT.0b013e3181d16999

26. Takiishi T, Gysemans C, Bouillon R, et al. Vitamin D and diabetes. Endocrinol Metab Clin North Am. 2010;39(2):419-446. PubMed doi:10.1016/j.ecl.2010.02.013

27. Karhapää P, Pihlajamäki J, Pörsti I, et al. Diverse associations of 25-hydroxyvitamin D and 1,25-dihydroxy-vitamin D with dyslipidaemias. J Intern Med. 2010;268(6):604-610. PubMed doi:10.1111/j.1365-2796.2010.02279.x

28. Diamond TH, Ho KW, Rohl PG, et al. Annual intramuscular injection of a megadose of cholecalciferol for treatment of vitamin D deficiency: efficacy and safety data. Med J Aust. 2005;183(1):10-12. PubMed

29. Hathcock JN, Shao A, Vieth R, et al. Risk assessment for vitamin D. Am J Clin Nutr. 2007;85(1):6-18. PubMed

30. Jones G. Pharmacokinetics of vitamin D toxicity. Am J Clin Nutr. 2008;88(suppl):582S-586S. PubMed

31. Rajasree S, Rajpal K, Kartha CC, et al. Serum 25-hydroxyvitamin D3 levels are elevated in South Indian patients with ischemic heart disease. Eur J Epidemiol. 2001;17(6):567-571. PubMed doi:10.1023/A:1014559600042

32. Stolzenberg-Solomon RZ, Jacobs EJ, Arslan AA, et al. Circulating 25-hydroxyvitamin D and risk of pancreatic cancer: Cohort Consortium Vitamin D Pooling Project of Rarer Cancers. Am J Epidemiol. 2010;172(1):81-93. PubMed doi:10.1093/aje/kwq120

33. Wang L, Manson JE, Song Y, et al. Systematic review: Vitamin D and calcium supplementation in prevention of cardiovascular events. Ann Intern Med. 2010;152(5):315-323. PubMed

34. Pittas AG, Chung M, Trikalinos T, et al. Systematic review: Vitamin D and cardiometabolic outcomes. Ann Intern Med. 2010;152(5):307-314. PubMed

35. Chung M, Balk EM, Brendel M, et al. Vitamin D and Calcium: A Systematic Review of Health Outcomes. Evidence Report No. 183. (Prepared by the Tufts Evidence-Based Practice Center under Contract No. HHSA 290-2007-10055-I.) AHRQ Publication No. 09-E015. Rockville, MD: Agency for Healthcare Research and Quality; 2009.

36. Jorde R, Sneve M, Torjesen P, et al. No improvement in cardiovascular risk factors in overweight and obese subjects after supplementation with vitamin D3 for 1 year. J Intern Med. 2010;267(5):462-472. PubMed doi:10.1111/j.1365-2796.2009.02181.x

37. Tzotzas T, Papadopoulou FG, Tziomalos K, et al. Rising serum 25-hydroxy-vitamin D levels after weight loss in obese women correlate with improvement in insulin resistance. J Clin Endocrinol Metab. 2010;95(9):4251-4257. PubMed doi:10.1210/jc.2010-0757

38. Ginde AA, Scragg R, Schwartz RS, et al. Prospective study of serum 25-hydroxyvitamin D level, cardiovascular disease mortality, and all-cause mortality in older US adults. J Am Geriatr Soc. 2009;57(9):1595-1603. PubMed doi:10.1111/j.1532-5415.2009.02359.x

39. Dobnig H, Pilz S, Scharnagl H, et al. Independent association of low serum 25-hydroxyvitamin d and 1,25-dihydroxyvitamin d levels with all-cause and cardiovascular mortality. Arch Intern Med. 2008;168(12):1340-1349. PubMed doi:10.1001/archinte.168.12.1340

40. Manson JE. Vitamin D and the heart: why we need large-scale clinical trials. Cleve Clin J Med. 2010;77(12):903-910. PubMed doi:10.3949/ccjm.77gr.10004

Related Articles

Volume: 14

Quick Links: Cardiology , Medical


Buy this Article as a PDF